<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Fagron Sa — News on 6ix</title>
    <link>https://6ix.com/company/fagron-sa</link>
    <description>Latest news and press releases for Fagron Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/fagron-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d68df2beedb30cb6fef65e.webp</url>
      <title>Fagron Sa</title>
      <link>https://6ix.com/company/fagron-sa</link>
    </image>
    <item>
      <title>Pete Pharma and Fagron Enter Strategic Distribution Partnership to Expand Access to Pharmaceutical 3D Printing Across North America</title>
      <link>https://6ix.com/company/fagron-sa/news/pete-pharma-and-fagron-enter-strategic-distribution-partnership-to-expand-access-to-pharmaceutical-3d-printing-across-north-america</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/pete-pharma-and-fagron-enter-strategic-distribution-partnership-to-expand-access-to-pharmaceutical-3d-printing-across-north-america</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>PHOENIX, April 16, 2026--Pete Pharma, a pharmaceutical innovation and IP development company focused on modernizing dosage forms through advanced 3D pharmaceutical printing, delivery systems, and scalable manufacturing platforms, today announced a strategic distribution and commercialization partnership with Fagron, Inc., a global leader in pharmaceutical compounding and personalized medicine.</description>
    </item>
    <item>
      <title>Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-convenes-ordinary-and-extraordinary-general-meeting-on-11-may-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-convenes-ordinary-and-extraordinary-general-meeting-on-11-may-2026</guid>
      <pubDate>Fri, 10 Apr 2026 05:00:00 GMT</pubDate>
      <description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its shareholders and holders of subscription rights to attend its Ordinary General Meeting and Extraordinary General Meeting, to be held on Monday, 11 May 2026, starting at 15:00 CEST. The Extraordinary General Meeting will be held before notary and will take place immediately following the Ordinary General Meet</description>
    </item>
    <item>
      <title>Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-reports-solid-first-quarter-revenue-of-euro263-million-reflecting-10percent-topline-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-reports-solid-first-quarter-revenue-of-euro263-million-reflecting-10percent-topline-growth</guid>
      <pubDate>Thu, 09 Apr 2026 05:00:00 GMT</pubDate>
      <description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2026. Key Highlights Revenue of €263.4 million, up 10.3% on a reported basis (15.0% at CER1), supported by incremental M&amp;A contribution and outstanding performance in Latin America</description>
    </item>
    <item>
      <title>Fagron increases share capital through exercise subscription rights</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-increases-share-capital-through-exercise-subscription-rights-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-increases-share-capital-through-exercise-subscription-rights-1</guid>
      <pubDate>Tue, 31 Mar 2026 17:00:00 GMT</pubDate>
      <description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 104,200 new shares have been issued on 31 March 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,462,601.84. The total number of shares with voting rights after the issue amounts to</description>
    </item>
    <item>
      <title>Fagron publishes its Annual Report 2025</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-publishes-its-annual-report-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-publishes-its-annual-report-2025</guid>
      <pubDate>Fri, 06 Mar 2026 06:00:00 GMT</pubDate>
      <description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron&apos;s annual financial results for the financial year 2025 on February 12, 2026. The Annual Report is available on Fagron&apos;s website in both Dutch (official version, including the ESEF-tagged version) and English. It compris</description>
    </item>
    <item>
      <title>Fagron completes acquisition of Vepakum</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-completes-acquisition-of-vepakum</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-completes-acquisition-of-vepakum</guid>
      <pubDate>Tue, 03 Mar 2026 06:00:00 GMT</pubDate>
      <description>Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 March 2026 – 7:00AM Fagron completes acquisition of Vepakum Fagron, the leading global player in pharmaceutical compounding, announces the successful completion of its acquisition of Vepakum in Latin America. The transaction, announced in December 2025, was finalized following regulatory clearance from CADE in early February 2026. Vepakum operates two facilities in São Paulo, Brazil, and specializes in hi</description>
    </item>
    <item>
      <title>Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-completes-strategic-acquisition-of-pharmavit-europe-strengthening-its-leadership-in-highgrowth-nutraceutical-ingredients-across-emea</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-completes-strategic-acquisition-of-pharmavit-europe-strengthening-its-leadership-in-highgrowth-nutraceutical-ingredients-across-emea</guid>
      <pubDate>Thu, 26 Feb 2026 17:30:00 GMT</pubDate>
      <description>Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw materials based in the Netherlands. Pharmavit Europe su</description>
    </item>
    <item>
      <title>Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-continues-its-outstanding-performance-in-fy-2025-with-92percent-topline-growth-and-109percent-increase-in-rebitda-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-continues-its-outstanding-performance-in-fy-2025-with-92percent-topline-growth-and-109percent-increase-in-rebitda-1</guid>
      <pubDate>Thu, 12 Feb 2026 06:00:00 GMT</pubDate>
      <description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2025. Key Highlights Strong revenue growth with 9.2% reported growth (12.9% at CER1) to reach €952.2 million, ahead of guidance and supported by all regions</description>
    </item>
    <item>
      <title>Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-obtains-regulatory-clearance-for-the-acquisition-of-vepakum-in-brazil-and-completes-the-acquisition-of-magilab-in-hungary-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-obtains-regulatory-clearance-for-the-acquisition-of-vepakum-in-brazil-and-completes-the-acquisition-of-magilab-in-hungary-1</guid>
      <pubDate>Thu, 05 Feb 2026 06:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 5 February 2026 Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary Additionally, the completion of Vepakum is expected to take place shortly. Following these milestones, Injeplast and Amber remain subject to closing, together with Vepakum. Vepakum Vepakum operates two facilities in São Paulo, Brazil, and provides high-quality pack</description>
    </item>
    <item>
      <title>Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America</title>
      <link>https://6ix.com/company/fagron-sa/news/inside-information-fagron-announces-the-completion-of-the-acquisition-of-university-compounding-pharmacy-in-north-america-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/inside-information-fagron-announces-the-completion-of-the-acquisition-of-university-compounding-pharmacy-in-north-america-1</guid>
      <pubDate>Mon, 12 Jan 2026 06:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder focused on the health and wellness segment in California. The transaction was previously announced</description>
    </item>
    <item>
      <title>Fagron announces the completion of Purifarma</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-announces-the-completion-of-purifarma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-announces-the-completion-of-purifarma-1</guid>
      <pubDate>Tue, 06 Jan 2026 06:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 January 2026 – 7:00 AM CET Fagron announces the completion of Purifarma Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of Purifarma in Brazil, an important milestone in executing our disciplined M&amp;A strategy. The completion of this transaction follows competition clearance by CADE, the Brazilian antitrust authority, last October, and will strengthen</description>
    </item>
    <item>
      <title>Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-accelerates-global-expansion-with-two-strategic-acquisitions-and-a-key-north-american-licensing-milestone-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-accelerates-global-expansion-with-two-strategic-acquisitions-and-a-key-north-american-licensing-milestone-1</guid>
      <pubDate>Fri, 19 Dec 2025 06:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2025 – 7:00 AM CET Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Fagron, the leading global player in pharmaceutical compounding, is pleased to announce two strategic acquisitions that further strengthen its global footprint and diversify its capabilities. These transactions include Amber Compounding Pharmacy, a well-established</description>
    </item>
    <item>
      <title>Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-strengthens-emea-leadership-with-acquisitions-in-poland-and-hungary-and-announces-key-developments-for-its-north-american-business-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-strengthens-emea-leadership-with-acquisitions-in-poland-and-hungary-and-announces-key-developments-for-its-north-american-business-1</guid>
      <pubDate>Mon, 24 Nov 2025 06:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 24 November 2025 – 7:00 AM CET Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business Fagron, the global leader in pharmaceutical compounding, has reinforced its EMEA position with the acquisitions of a book of business from Amara (Poland) and Magilab (Hungary). These deals support Fagron’s strategy to diversify its presence</description>
    </item>
    <item>
      <title>Fagron completes share buy-back program</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-completes-share-buy-back-program-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-completes-share-buy-back-program-1</guid>
      <pubDate>Fri, 14 Nov 2025 17:39:00 GMT</pubDate>
      <description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 November 2025 – 6PM CET Fagron completes share buy-back program In the period from 10 November 2025 through 14 November 2025, Fagron purchased 44,000 of its owns shares at an average price of €20.7208 per share corresponding to a total amount of €911,717.00. A total of 200,000 Fagron shares have been repurchased under the buy-back program at an average price of € 20.6805 per share, corresponding to a total amount of € 4,136,</description>
    </item>
    <item>
      <title>Fagron’s share buy-back program: Weekly update</title>
      <link>https://6ix.com/company/fagron-sa/news/fagrons-share-buy-back-program-weekly-update-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagrons-share-buy-back-program-weekly-update-1</guid>
      <pubDate>Fri, 07 Nov 2025 17:39:00 GMT</pubDate>
      <description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 3 November 2025 through 7 November 2025, Fagron purchased 45,000 of its owns shares at an average price of €20.4413 per share corresponding to a total amount of €919,856.70. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was</description>
    </item>
    <item>
      <title>Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-reports-solid-third-quarter-performance-with-64percent-revenue-growth-and-confirms-full-year-outlook-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-reports-solid-third-quarter-performance-with-64percent-revenue-growth-and-confirms-full-year-outlook-1</guid>
      <pubDate>Thu, 09 Oct 2025 05:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 October 2025 – 7:00 AM CET Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2025. Key Highlights Q3 2025 organic growth at CER1 of 8.5% on a normalized basis2 and 5.7% including the GLP-1 impactRevenue for the third q</description>
    </item>
    <item>
      <title>Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-receives-brazilian-antitrust-clearance-for-purifarma-and-injeplast-acquisitions-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-receives-brazilian-antitrust-clearance-for-purifarma-and-injeplast-acquisitions-1</guid>
      <pubDate>Mon, 06 Oct 2025 05:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 October 2025 – 7:00 AM CET Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions Fagron, the leading global player in pharmaceutical compounding, announces that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil. The clearances represent an important step forward in executing Fagro</description>
    </item>
    <item>
      <title>Fagron announces the acquisition of UCP in North America and FDA inspection update</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-announces-the-acquisition-of-ucp-in-north-america-and-fda-inspection-update-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-announces-the-acquisition-of-ucp-in-north-america-and-fda-inspection-update-1</guid>
      <pubDate>Thu, 25 Sep 2025 05:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET Fagron announces the acquisition of UCP in North America and FDA inspection update Fagron, the leading global player in pharmaceutical compounding, is pleased to announce a strategic acquisition that will significantly reinforce its presence in North America. The company has signed the acquisition of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder spec</description>
    </item>
    <item>
      <title>Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-delivers-strong-performance-with-11percent-topline-growth-and-12percent-increase-in-rebitda-for-h1-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-delivers-strong-performance-with-11percent-topline-growth-and-12percent-increase-in-rebitda-for-h1-2025-1</guid>
      <pubDate>Thu, 31 Jul 2025 05:00:00 GMT</pubDate>
      <description>Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2025. Key Highlights Strong revenue performance with 10.9% reported revenue growth (14.4% at CER1) and 11.3% organic growth at CER 12.3% REBITDA increa</description>
    </item>
    <item>
      <title>Fagron shareholders approve all voting items AGM</title>
      <link>https://6ix.com/company/fagron-sa/news/fagron-shareholders-approve-all-voting-items-agm-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fagron-sa/news/fagron-shareholders-approve-all-voting-items-agm-1</guid>
      <pubDate>Mon, 12 May 2025 17:00:00 GMT</pubDate>
      <description>Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET Fagron shareholders approve all voting items AGM Fagron, the leading global player in pharmaceutical compounding, held its annual general shareholders meeting today, where all the voting items were approved. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.35 per share for the fiscal year 2024, the remuneration policy and</description>
    </item>
  </channel>
</rss>